Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04276090 · ClinicalTrials.gov registry record · NA
Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma
A NA study, sponsored by Michael J Cavnar, MD.
- Terminated
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT04276090: Clinical Trial NA study, sponsored by Michael J Cavnar, MD.
NCT04276090 is a NA study that was terminated before completion, run by Michael J Cavnar, MD. The registered enrollment target is 21 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04276090, a NA study, was terminated before completion, sponsored by Michael J Cavnar, MD.
- TERMINATED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
Due to discontinuation of the Codman C3000 pump, an alternate device is necessary to continue serving patients in need of hepatic arterial infusion chemotherapy. This study aims to test the safety of hepatic artery infusion pump placement, a standard surgical procedure, and intraarterial chemotherapy initiation with the standard medication floxuridine (FUDR), using the Medtronic Synchromed II pump combined with the Codman arterial catheter in patients with unresectable (not removable by surgery) liver metastases from colorectal cancer and unresectable intrahepatic cholangiocarcinoma. This study will determine if complication and pump loss rates will be similar to previously published rates for the Codman system.
Primary Outcome
The percent of patients who complete the 1st cycle of hepatic artery chemotherapy will be tabulated. This is a conglomerate safety endpoint which is a surrogate for any complication that prevents delivery of hepatic artery chemotherapy via the device combination.
Interventions
- DEVICE Hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter.
- DRUG Hepatic artery infusion pump floxuridine and dexamethasone
- DRUG Systemic chemotherapy for colorectal liver metastases
- DRUG Systemic chemotherapy for intrahepatic cholangiocarcinoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2020-05-01 |
| Est. Completion | 2022-06-14 |
| Phase | NA |
Why NCT04276090 stopped before completion
NCT04276090 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 4 interventions - of which Hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter. is the first listed.
NCT04276090 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04276090 about?
NCT04276090 is a clinical study titled "Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma". Due to discontinuation of the Codman C3000 pump, an alternate device is necessary to continue serving patients in need of hepatic arterial infusion chemotherapy. This study aims to test the safety of hepatic artery infusion pump placement, a standard surgical procedure, and intraarterial chemotherap...
What is the current status of trial NCT04276090?
This trial is currently terminated. It is a NA study. The enrollment target is 21 participants. The study started on 2020-05-01. Estimated completion is 2022-06-14.
What interventions are being tested in trial NCT04276090?
The interventions under investigation include: Hepatic artery infusion pump placement using the Synchromed II pump and the Codman tapered arterial catheter. (DEVICE), Hepatic artery infusion pump floxuridine and dexamethasone (DRUG), Systemic chemotherapy for colorectal liver metastases (DRUG), Systemic chemotherapy for intrahepatic cholangiocarcinoma (DRUG).
Who is sponsoring clinical trial NCT04276090?
This trial is sponsored by Michael J Cavnar, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04276090's enrollment target sits among peer trials
21 1762nd of 2000 higher than 233 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI